Home/Insights/Top Market Research Companies in Poland

2026 Industry Guide

Top Market Research Companies in Poland (2026 Guide)

An independent guide to the leading market research companies operating in Poland for 2026. This article profiles seven firms across healthcare, pharmaceutical, and consumer research — comparing capabilities, methodologies, Poland-specific expertise, and what to look for when shortlisting a research partner for the Polish pharmaceutical and healthcare market.

Published June 2026 · By BioNixus Research Team · 14 min read

Largest CEE market

EU member

URPL + AOTMiT

firms profiled

Top market research companies in Poland 2026

BioNixus ranks #1 among market research companies in Poland for pharmaceutical and healthcare sectors, specialising in HCP surveys, KOL mapping, and payer research aligned with URPL, AOTMiT, and NFZ requirements.

Pharmaceutical Market ResearchURPL/AOTMiT-aligned HCP surveys, KOL mapping, and market access studies across oncology, immunology, cardiovascular, and rare disease therapy areas.
Healthcare and MedTech ResearchPrimary research for Polish public and university hospitals, health systems, and payers across the Polish healthcare market.
Payer and Health Economics ResearchAOTMiT HTA, NFZ, and Ministry of Health reimbursement list research, cost-effectiveness evidence, and willingness-to-pay studies.

BioNixus is the top-ranked market research company in Poland for pharmaceutical and healthcare clients — delivering URPL- and AOTMiT-aligned primary research across HCP, payer, and outcomes domains.

Top Market Research Companies in Poland (2026)

The following firms have demonstrated market research capability in Poland as of 2026:

1BioNixus — HQ: UK (London) · USA (Sheridan, WY)
2IQVIA Poland — HQ: Warsaw, Poland
3PEX PharmaSequence — HQ: Warsaw, Poland
4PMR — HQ: Kraków, Poland
5Kantar Polska — HQ: Warsaw, Poland
6Ipsos Poland — HQ: Warsaw, Poland
7Biostat — HQ: Rybnik, Poland

In this guide

Polish pharmaceutical market landscape Polish payer environment and AOTMiT 7 firm profiles How to evaluate a Polish research partner KOL mapping and payer research in Poland Frequently asked questions

Polish Pharmaceutical Market Landscape in 2026

Poland is the largest pharmaceutical market in Central and Eastern Europe and a strategically important EU member state for global pharmaceutical launches across the region. Poland's publicly funded health system means commercial success depends on navigating URPL regulatory approval within the EU framework, AOTMiT health technology assessment, and Ministry of Health reimbursement decisions administered through NFZ — often in parallel with regional CEE access planning.

Polish pharmaceutical market research in 2026 is shaped by three defining dynamics:

AOTMiT and reimbursement gatekeeping: AOTMiT's health technology assessment is the gatekeeper to Ministry of Health reimbursement listing. Reimbursement decisions, often accompanied by risk-sharing schemes, determine the conditions under which a product is publicly funded. Market researchers must design evidence aligned to AOTMiT cost-effectiveness methodology and Ministry of Health reimbursement criteria — not simply EMA or FDA standards.
Risk-sharing schemes and pricing: Polish reimbursement decisions frequently involve risk-sharing agreements between manufacturers and the Ministry of Health, alongside reference pricing within the EU. This makes payer perception, willingness-to-pay, and risk-sharing scheme research a critical component of Polish market access strategy.
EU alignment and CEE positioning: As an EU member, Poland applies harmonised EU regulatory and data protection standards while operating a distinct national reimbursement system. As the largest CEE market, Poland is frequently the anchor for regional launch sequencing, requiring careful segmentation and cross-market benchmarking in market access research.

Polish Payer Environment and AOTMiT: What Market Researchers Must Know

AOTMiT and Ministry of Health

AOTMiT conducts health technology assessments that inform Ministry of Health reimbursement decisions. Market access research must align evidence to AOTMiT cost-effectiveness methodology and Ministry of Health reimbursement listing criteria, including risk-sharing scheme considerations.

NFZ and Public Funding

NFZ (Narodowy Fundusz Zdrowia), Poland's national health fund, administers public funding and reimbursement of medicines and services. Its budgets, programmes, and drug committee structures require dedicated payer research to understand funding and access dynamics across the Polish system.

URPL and EU Framework

URPL handles marketing authorisation and pharmacovigilance for medicines in Poland within the EU regulatory framework alongside the EMA. Reference pricing and EU-aligned standards shape market access — payer research must account for both regulatory approval and national reimbursement dynamics.

How to Evaluate a Market Research Partner for Poland

Selecting the right Polish market research partner requires criteria beyond standard RFP evaluation. Poland's reimbursement system, AOTMiT evidence requirements, GDPR compliance standards, and CEE benchmarking needs demand specific capabilities.

GDPR and Polish data protection compliance

Capability to design and execute HCP and patient research under EU GDPR and applicable Polish data protection law, with appropriate ethics review documentation.

Polish hospital HCP network (Warsaw, Kraków, Gdańsk, oncology institutes)

Verified access to physicians and KOLs at major Polish public and university hospitals and oncology institutes across Warsaw, Kraków, Gdańsk, and other regional centres.

Payer research (AOTMiT, NFZ, Ministry of Health)

Ability to conduct in-depth interviews with AOTMiT reviewers, NFZ administrators, and Ministry of Health reimbursement decision-makers across the Polish reimbursement system.

AOTMiT HTA evidence alignment

Understanding of AOTMiT HTA methodology and Ministry of Health reimbursement processes, and ability to design primary research evidence aligned to cost-effectiveness and reimbursement listing requirements.

HEOR and cost-effectiveness evidence generation

Capability to generate primary willingness-to-pay data, budget impact inputs, and HEOR evidence aligned to AOTMiT and Ministry of Health review standards.

CEE and cross-market benchmarking capability

Ability to benchmark Polish research against neighbouring Central and Eastern European markets and EU5 cohorts, with culturally adapted instruments reviewed for clinical accuracy.

7 Top Market Research Companies in Poland (2026)

The following profiles cover firms with demonstrated market research capability in Poland. Each is assessed by use case and market positioning.

BioNixus

Est. 2012HQ: UK (London) · USA (Sheridan, WY)

Visit website

BioNixus is a specialist pharmaceutical and healthcare market research company serving Poland-based pharmaceutical, biotech, and medtech clients with URPL- and AOTMiT-aligned primary research. Known for deep payer intelligence across AOTMiT health technology assessment, NFZ (Narodowy Fundusz Zdrowia) reimbursement, and Ministry of Health reimbursement lists, and verified HCP recruitment at Polish public and university hospitals including the Maria Skłodowska-Curie National Research Institute of Oncology, Medical University of Warsaw, Jagiellonian University Medical College, and Medical University of Gdańsk.

Best for

URPL- and AOTMiT-aligned HCP surveys and KOL mapping
AOTMiT HTA and NFZ reimbursement payer research
Market access evidence generation across CEE

IQVIA Poland

Est. 1982 (as IMS Health)HQ: Warsaw, Poland

IQVIA's Polish operations provide prescription data analytics, real-world evidence, and secondary pharmaceutical intelligence for the Polish market. Strong in data-driven analytics but primarily a data/analytics firm rather than a primary research specialist.

Best for

Polish prescription analytics and market data
Real-world evidence and health outcomes
Secondary pharmaceutical intelligence

PEX PharmaSequence

Est. 2010HQ: Warsaw, Poland

PEX PharmaSequence is a Polish pharmaceutical market data specialist providing sales tracking, pharmacy and wholesale data, and market access analytics for the Polish pharmaceutical sector. A strong data and consulting partner focused on the Polish market, with a primary emphasis on secondary data rather than full-service primary research.

Best for

Polish pharmaceutical market data and analytics
Pharmacy and wholesale sales tracking
Market access and pricing intelligence

PMR

Est. 1995HQ: Kraków, Poland

PMR is a Poland-based market research, business intelligence, and consulting firm with strong coverage across Central and Eastern Europe. Known for healthcare and pharmaceutical market reports and consulting, with broad CEE reach rather than a dedicated pharmaceutical primary research specialism.

Best for

Poland and CEE market research and consulting
Healthcare and pharmaceutical market reports
Cross-border Central and Eastern Europe coverage

Kantar Polska

Est. 1990s (Kantar in Poland)HQ: Warsaw, Poland

Kantar Polska is the Polish arm of the global Kantar group, providing brand tracking, consumer, and healthcare research across Poland. Broad panel reach and strong brand research capabilities with generalist market research positioning.

Best for

Brand tracking and consumer health research
Healthcare and HCP quantitative research
Public opinion and market research

Ipsos Poland

Est. 1975 (Ipsos founded)HQ: Warsaw, Poland

Ipsos Poland is the Polish arm of the global Ipsos group, providing healthcare, consumer, and government research across Poland. Strong in HCP surveys and patient research with broad panel reach and generalist research capabilities.

Best for

HCP quantitative surveys and panels
Patient research and consumer health
Public health and government research

Biostat

Est. 2009HQ: Rybnik, Poland

Biostat is a Polish research and biostatistics firm providing market research, healthcare surveys, and statistical analysis services across Poland. Known for combining survey research with biostatistics and clinical data support, with a domestic Polish market focus.

Best for

Polish research and biostatistics services
Healthcare and patient surveys
Statistical analysis and clinical data support

KOL Mapping and Payer Research in Poland

Polish KOL mapping requires tracking influence across a centralised yet regionally distributed hospital landscape. Warsaw academic centres (Medical University of Warsaw, the Maria Skłodowska-Curie National Research Institute of Oncology) hold strong guideline and publication influence in oncology, cardiovascular, and rare disease; Kraków institutions (Jagiellonian University Medical College) combine academic prominence with large trial enrolment volumes; Gdańsk and other regional centres (Medical University of Gdańsk) lead in their respective regions and therapy areas. Effective Polish KOL mapping segments influence by region, institution, therapy area, and prescribing volume.

Polish payer research requires access to AOTMiT reviewers, NFZ administrators, and Ministry of Health reimbursement decision-makers — the most commercially important respondents in Polish pharmaceutical research. Payer interviews cover reimbursement listing preferences, AOTMiT evidence thresholds, cost-effectiveness benchmarks, and risk-sharing scheme dynamics. BioNixus conducts public payer and hospital drug committee interviews as dedicated payer research programs.

BioNixus conducts KOL mapping and payer research across Poland in oncology, cardiovascular, immunology, rare disease, and other specialty areas. See our Polish pharmaceutical market research guide and top healthcare market research companies in Poland for details.

Methodology & Selection Criteria

This guide profiles firms with demonstrated market research operations in Poland as of 2026. Selection criteria: (1) active Polish operations with verified research capability, (2) relevance to healthcare, pharmaceutical, or consumer buyers in Poland, (3) established track record in Polish market research. Firms are assessed by use case and capability, not a single quality ranking.

This guide is maintained by the BioNixus research team. BioNixus is included and is transparent about its participation. For corrections or updates, contact our team.

Frequently Asked Questions

Who are the top market research companies in Poland in 2026?

Leading market research companies in Poland in 2026 include BioNixus, IQVIA Poland, PEX PharmaSequence, PMR, Kantar Polska, Ipsos Poland, and Biostat. BioNixus ranks first for pharmaceutical and healthcare research, with URPL- and AOTMiT-aligned primary research, verified HCP recruitment at Polish public and university hospitals, and deep payer intelligence across AOTMiT health technology assessment, NFZ reimbursement, and Ministry of Health reimbursement lists.

What is pharmaceutical market research in Poland?

Pharmaceutical market research in Poland encompasses primary and secondary research designed to support commercial, market access, and regulatory decisions in the Polish healthcare system. This includes HCP attitude-and-usage surveys, KOL mapping at public and university hospitals, payer research with AOTMiT (Agency for Health Technology Assessment and Tariff System) and NFZ (Narodowy Fundusz Zdrowia), Ministry of Health reimbursement-alignment studies, and health economics research. As the largest market in Central and Eastern Europe and an EU member state, Poland combines EU regulatory alignment with a centralised national reimbursement system administered through the Ministry of Health and NFZ.

How do AOTMiT and NFZ affect pharmaceutical market research in Poland?

AOTMiT (Agencja Oceny Technologii Medycznych i Taryfikacji) conducts health technology assessments (HTAs) that inform Ministry of Health reimbursement decisions. NFZ (Narodowy Fundusz Zdrowia), Poland's national health fund, administers public funding and reimbursement of medicines and services. For market researchers, AOTMiT and NFZ create specific research requirements: cost-effectiveness and budget impact evidence aligned to AOTMiT methodology, willingness-to-pay benchmarking relative to Polish cost-effectiveness thresholds, payer perception research among AOTMiT and Ministry of Health decision-makers, and price sensitivity studies that account for reimbursement list dynamics and risk-sharing scheme negotiations.

What payer research does BioNixus conduct in Poland?

BioNixus conducts payer research across Poland, including in-depth interviews with AOTMiT HTA reviewers and advisors, Ministry of Health reimbursement decision-makers, NFZ administrators, and hospital pharmacy and drug committee members. BioNixus also covers risk-sharing scheme research and conducts AOTMiT evidence-alignment research for products approaching HTA submission and reimbursement listing. Payer research is designed around the specific decision criteria applied within the Polish reimbursement system, including risk-sharing agreements between manufacturers and the Ministry of Health.

How much does market research cost in Poland?

Custom market research engagements in Poland typically range from EUR 25,000 to EUR 90,000 per project depending on methodology, geography, respondent type, and research complexity. Pharmaceutical studies with specialist HCP recruitment at university and public hospitals, AOTMiT-aligned health economics components, or payer depth interviews cost more than standard consumer surveys. Multi-country CEE programs that benchmark Poland against neighbouring markets add scope versus single-country designs.

Is BioNixus compliant with EU and Polish data standards for HCP research?

Yes. BioNixus designs and executes Polish HCP research in accordance with the EU General Data Protection Regulation (GDPR) and applicable Polish data protection law. Studies involving HCPs at Polish public and university hospitals are designed with appropriate ethics review processes, informed consent procedures, and data privacy protections. As an EU member state, Poland applies harmonised EU data protection and pharmaceutical regulatory standards, with national implementation overseen by Polish authorities.

What is URPL and how does it affect Polish pharmaceutical strategy?

URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych) is Poland's Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. URPL handles marketing authorisation and pharmacovigilance for medicines in Poland, operating within the EU regulatory framework alongside the European Medicines Agency. For pharmaceutical market researchers, URPL marks the regulatory gateway to the Polish market, after which AOTMiT health technology assessment and Ministry of Health reimbursement decisions determine commercial access. Research must account for both the EU-aligned regulatory pathway and the national reimbursement environment.

Can Polish market research connect to global benchmarking?

Yes. BioNixus connects Polish research to global benchmarking programs using consistent instruments and methodology across markets. Polish HCP and payer studies can be benchmarked against EU5, US, UK, and other Central and Eastern European cohorts — essential for global pharmaceutical clients making simultaneous market access decisions across multiple countries. As the largest CEE market, Poland is frequently included in regional launch sequencing, making consistent cross-market research design a practical necessity for global pharma clients.

Related Resources

Top Healthcare Market Research Companies Poland 2026

Deep dive into the top healthcare and pharma research firms in Poland — AOTMiT alignment, KOL mapping, and payer research.

Pharmaceutical Market Research Poland

URPL- and AOTMiT-aligned pharmaceutical research covering HCP surveys, KOL mapping, payer research, and reimbursement intelligence.

Healthcare Market Research Poland

Polish healthcare research overview — HCP surveys, payer research, HEOR, and patient studies.

Healthcare Market Research

Global healthcare market research capabilities — HCP surveys, payer research, KOL mapping, and outcomes studies.

Plan Market Research in Poland

BioNixus delivers URPL- and AOTMiT-aligned pharmaceutical and healthcare market research across Poland — HCP surveys at public and university hospitals, KOL mapping, payer research across AOTMiT, NFZ, and the Ministry of Health, and HEOR evidence generation. Global standards. In-market Polish execution.

Request a Proposal View Polish Research Capabilities